![MRP-7 Enhances Paclitaxel Resistance and Aggressive Phenotypes of EC... | Download Scientific Diagram MRP-7 Enhances Paclitaxel Resistance and Aggressive Phenotypes of EC... | Download Scientific Diagram](https://www.researchgate.net/publication/356841280/figure/fig4/AS:1098740588916740@1638971578417/MRP-7-Enhances-Paclitaxel-Resistance-and-Aggressive-Phenotypes-of-EC-Cells-A-MRP-7_Q320.jpg)
MRP-7 Enhances Paclitaxel Resistance and Aggressive Phenotypes of EC... | Download Scientific Diagram
![Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666675822000352-fx1.jpg)
Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect
![Use of the Tubulin Bound Paclitaxel Conformation for Structure-Based Rational Drug Design: Chemistry & Biology Use of the Tubulin Bound Paclitaxel Conformation for Structure-Based Rational Drug Design: Chemistry & Biology](https://www.cell.com/cms/attachment/704e2ed1-b52b-4d07-87d4-e911fc38c8bd/gr1_lrg.gif)
Use of the Tubulin Bound Paclitaxel Conformation for Structure-Based Rational Drug Design: Chemistry & Biology
![Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases - Man Yee Merl, Renee Moye, Anindya Chatterjee, Kenyon D Ogburn, 2020 Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases - Man Yee Merl, Renee Moye, Anindya Chatterjee, Kenyon D Ogburn, 2020](https://journals.sagepub.com/cms/10.1177/2050313X20970753/asset/images/large/10.1177_2050313x20970753-fig1.jpeg)
Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases - Man Yee Merl, Renee Moye, Anindya Chatterjee, Kenyon D Ogburn, 2020
![Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Oncogene Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.onc.1209498/MediaObjects/41388_2006_Article_BF1209498_Fig1_HTML.jpg)
Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Oncogene
![Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study | British Journal of Cancer Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0815-9/MediaObjects/41416_2020_815_Fig1_HTML.png)
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study | British Journal of Cancer
![IJMS | Free Full-Text | Paclitaxel Induces Apoptosis in Breast Cancer Cells through Different Calcium—Regulating Mechanisms Depending on External Calcium Conditions IJMS | Free Full-Text | Paclitaxel Induces Apoptosis in Breast Cancer Cells through Different Calcium—Regulating Mechanisms Depending on External Calcium Conditions](https://www.mdpi.com/ijms/ijms-15-02672/article_deploy/html/images/ijms-15-02672f1a.png)
IJMS | Free Full-Text | Paclitaxel Induces Apoptosis in Breast Cancer Cells through Different Calcium—Regulating Mechanisms Depending on External Calcium Conditions
![IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/3/e003924/F1.large.jpg)
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer | Journal for ImmunoTherapy of Cancer
![IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer](https://www.mdpi.com/ijerph/ijerph-17-02213/article_deploy/html/images/ijerph-17-02213-g001.png)